Abivax SA (ABVX) vs argenx (ARGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Abivax SA (ABVX) has outperformed argenx (ARGX) over the past year, gaining 2.9% versus a gain of 2.5%. argenx is the larger company by market cap ($51.48 billion vs $7.77 billion), about 6.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABVX | ARGX |
|---|---|---|
| Share price | $89.05 | $818.63 |
| Market cap | $7.77B | $51.48B |
| 1-day change | +2.34% | -11.83% |
| YTD return | -33.97% | -2.65% |
| 1-year return | +2.94% | +2.46% |
| 5-year return | — | +178.69% |
| P/E ratio (TTM) | — | 35.42 |
| Forward P/E | — | 23.58 |
| EPS (TTM) | $-6.08 | $23.11 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $1.29B |
| 52-week high | $148.83 | $1,072.75 |
| 52-week low | $69.81 | $661.85 |
| Distance from 52-week high | -40.17% | -23.69% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +84.17% | +43.17% |
| Average volume | 1.11M | 283.40K |
| Shares outstanding | 87.27M | 62.89M |
| Employees | 98 | 1,863 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- argenx is about 6.6 times larger than Abivax SA by market value ($51.48B vs $7.77B).
About Abivax SA
ABVX stock →ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease.
Healthcare · Biotechnology · 98 employees
About argenx
ARGX stock →argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP).
Healthcare · Biotechnology · 1,863 employees
ABVX vs ARGX FAQ
Which is bigger, Abivax SA or argenx?
argenx (ARGX) is larger, with a market capitalization of $51.48B compared with $7.77B for Abivax SA (ABVX).
Which stock has performed better over the past year, ABVX or ARGX?
ABVX returned +2.94% over the past 12 months, compared with +2.46% for ARGX (price return, excluding dividends). Past performance does not predict future results.
Are Abivax SA and argenx in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.